As DELEX Pharma engages in the hospital sector, it upholds the highest ethical standards for patient safety by providing a diverse range of critical care products approved by the Philippine Food and Drug Administration (FDA). This strict adherence to regulatory requirements not only ensures patient well-being but also strengthens the trust and credibility the company has built with hospitals across the country, contributing to steady product sales and revenue growth.
These high-quality, cost-effective products address the growing demands of critical care, offering innovative solutions for rising ICU cases in the country such as hypertension, cardiac dysfunction, and neurological conditions.
The hospital market in the Philippines is projected to grow by 9.25% from 2024 to 2029, reaching a market volume of US$7.9 billion by 2029, according to recent research. In addition to supplying hospitals, critical care products are strategically placed in drugstore chains nationwide to enhance accessibility. One of the key distribution channels is Mercury Drug, the largest pharmacy chain in the country with thousands of branches, including those in remote areas. This extensive network significantly increases market reach and drives sales growth for the organizations critical care products.
These products are manufactured by multinational companies, such as Rompharm Ilac San. Ve Tic. Ltd. Sti. and United Biotech Pvt. Ltd., to name a few, certified by WHO-CGMP (World Health Organization – Current Good Manufacturing Practices). Adhering strictly to FDA standards, these companies ensure the quality and effectiveness of their products in critical care management. For more information or specific inquiries about these products, visit the DELEX Pharma website.
Purpose of Product: Provides relief from anginal chest pain through vasodilation
FDA Registration Number: DRP-13372
Purpose of Product: Treats severe hypertension, including hypertensive disorders in pregnancy
FDA Registration Number: DR-XY48744
Purpose of Product: Used in the management of severe sodium chloride depletion when electrolyte restoration is required in following cases like low salt syndrome and hyponatremia
FDA Registration Number: DR-XY48414
Purpose of Product: he product is the first-choice inotrope for patients with measured or suspected low cardiac output
FDA Registration Number: DR- XY38709
Purpose of Product: Treatment for a prolonged decrease in intracranial pressure during acute episodes of intracranial hypertension, including Traumatic Brain Injury (TBI)
FDA Registration Number: DR-XY33427
Purpose of Product: The first-line vasopressor for hypotension due to shock
FDA Registration Number: DR-XY38818
Purpose of Product: Recommended drug for the treatment of hypertensive crisis, eclampsia, and : perioperative hypertension
FDA Registration Number: DRP-6940
BNCM is an Asset Management Company that secures its assets by investing in companies with strong growth potentials, robust revenues, significant profits, proven track records, and promising business models with highly experienced management teams that will exceptionally qualify for quotation and listing on the OTC or NASDAQ markets within the next 2 to 3 years. The growth of these companies will directly provide more employment opportunities to the communities, improve the country’s economy, and bring greater social change.
For more information, visit: https://www.bncm.net/
DELEX is a Delaware-registered company, and the holding company of DLX Holdings, Inc. (DLX). DLX is a Philippine-based parent company that holds a 60% controlling interest in Delex Pharma International, Inc. an ISO 9001-2015 Certified company, which also holds a controlling interest in JMN Brother’s Pharma Limited, Inc. DLX and its subsidiaries are involved in the development and distribution of pharmaceutical and healthcare products in the Philippines.
For more information, visit: https://delexhealth.com
